Exhibit 99.1

PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update

Berkeley Heights, NJ, May 14, 2019
- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced its financial results for the first quarter ended March 31, 2019.

Q1 2019 and Recent Business Highlights


Successfully completed merger with Edge Therapeutics and listed on the Nasdaq Capital Market;

Strengthened Board of Directors with the appointment of industry veteran Stephen Glover.

“The first quarter of 2019 was an exciting period for PDS, as we successfully completed our merger with Edge Therapeutics and became a public company. Simultaneously, we strengthened both our management team and Board of Directors with industry veterans who we believe will help guide our strategic direction moving forward,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. “As we look ahead, we are preparing to initiate three clinical studies of PDS0101 in the fourth quarter of this year, which includes; a planned phase 2 combination study to evaluate PDS0101 in combination with Keytruda® in the treatment of head and neck cancer, a phase 2 study to evaluate PDS0101 in advanced HPV-associated cancers, and an anticipated registration trial to evaluate PDS0101 monotherapy in the treatment of high-grade cervical dysplasia.”

First Quarter 2019 Financial Review

For the first quarter of 2019, net income was approximately $6.8 million, or $1.82 per basic share and $1.47 per diluted share, compared to a net loss of approximately $(0.7) million, or $(0.24) per basic and diluted share for the first quarter of 2018.

Research and development expenses totaled approximately $1.0 million for the first quarter of 2019, compared to approximately $0.2 million for the same period in 2018, an increase of 412%. These expenses include employee-related expenses, licensing fees to use certain technology in PDS’ research and development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on PDS’ behalf.

For the first quarter of 2019, general and administrative expenses were approximately $3.9 million compared with approximately $0.5 million for the first quarter of 2018, an increase of 629%. The increase is primarily attributable to an increase in non-cash stock compensation expense of $2.3 million and bonuses of $0.4 million. In addition, there was an increase in D&O insurance of $0.1 million, professional consulting fees of $0.1 million, as well as legal fees of $0.4 million.

Total operating expenses for the first quarter of 2019 were approximately $4.9 million, compared to total operating expenses of approximately $0.7 million for the same period in 2018, an increase of 570%.

The Company recognized a gain on bargain purchase of approximately $11.7 million in connection with the merger with Edge. The gain represents the difference between the book value of Edge assets compared to the cash value of stock granted to legacy Edge shareholders.

As of March 31, 2019, the Company’s cash balance was approximately $26.6 million.



About PDS Biotechnology
PDS Biotechnology is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, cervical, anal, prostate, breast and other cancers.

PDS Biotechnology’s lead product candidate, PDS0101 (Versamune®-HPV) is a proprietary clinical stage immunotherapeutic administered by subcutaneous injection being developed to treat HPV-associated cancers such as head and neck cancers and anal cancers, both of which are widely reported to be increasing in frequency over the last decade, as well as cervical, penile, vaginal and vulvar cancers and their pre-cancerous conditions. In a human Phase 1/2a clinical study, PDS0101 monotherapy demonstrated potent in-vivo induction of the critical phenotype of tumor-attacking killer (CD8) T-cells, and induction of memory T-cells. No dose-limiting toxicities were observed in this study, suggesting potential for a rare combination of potency and safety among immune-oncology therapeutics.
For additional information about PDS, please visit www.pdsbiotech.com.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Company’s ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger; the Company’s ability to access capital markets, the timing for the Company to initiate two clinical trials for its lead asset, PDS0101; the successful implementation of the Company’s research and development programs and collaborations; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.



Media & Investor Relations Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: +1-646-536-7035 / +1-646-536-7037
Email: tbui@theruthgroup.com / alobo@theruthgroup.com




(Financial Statements to Follow)



PDS BIOTECHNOLOGY CORPORATION

Condensed Consolidated Balance Sheets

 
 
March 31, 2019
   
December 31, 2018
 
ASSETS
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
26,592,845
   
$
103,695
 
Prepaid expenses and other current assets
   
1,313,931
     
156,628
 
Total current assets
   
27,906,776
     
260,323
 
 
               
Property and equipment, net
   
412,735
     
29,508
 
Intangible assets, net
   
1,223,000
     
41,692
 
Right-to-use assets
   
1,347,557
     
-
 
Other assets
   
155,670
     
12,800
 
 
               
Total assets
 
$
31,045,738
   
$
344,323
 
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
LIABILITIES
               
Current liabilities:
               
Accounts payable
 
$
2,665,266
   
$
1,412,951
 
Accrued expenses
   
446,962
     
601,889
 
Restructuring reserve
   
1,948,596
     
-
 
Operating lease liability- short term
   
477,300
     
-
 
Total current liabilities
   
5,538,124
     
2,014,840
 
 
               
Noncurrent liability:
               
Deferred tax liability
   
157,000
     
-
 
Operating lease liability- long term
   
902,972
     
-
 
Convertible promissory notes payable
   
-
     
30,000
 
 
               
STOCKHOLDERS’ EQUITY
               
Preferred stock, 5,000,000  shares authorized at March 31, 2019 and December 31, 2018, 0 outstanding
   
-
     
-
 
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2019 and December 31, 2018, 5,172,938 shares and 3,417,187 shares issued and outstanding at March 31, 2019 and  December 31, 2018, respectively
   
1,707
     
1,128
 
Additional paid-in capital
   
38,642,411
     
19,311,529
 
Accumulated deficit
   
(14,196,476
)
   
(21,013,174
)
Total stockholders’ equity
   
24,447,642
     
(1,700,517
)
 
               
Total liabilities and stockholders’ equity
 
$
31,045,738
   
$
344,323
 



PDS BIOTECHNOLOGY CORPORATION 

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
 
2019
   
2018
 
Operating expenses:
           
Research and development expenses
 
$
1,030,003
   
$
201,138
 
General and administrative expenses
   
3,905,877
     
535,801
 
 
               
Total operating expenses
   
4,935,880
     
736,939
 
 
               
Loss from operations
   
(4,935,880
)
   
(736,939
)
 
               
Other income (expense):
               
Gain on bargain purchase
   
11,729,882
     
-
 
Interest income
   
23,302
     
6
 
Interest expense
   
(606
)
   
(959
)
 
               
Comprehensive income (loss)
 
$
6,816,698
   
$
(737,892
)
 
               
Per share information:
               
Net income (loss) per share , basic
 
$
1.82
   
$
(0.24
)
Net income (loss) per share , diluted
 
$
1.47
   
$
(0.24
)
Weighted average common shares outstanding, basic
   
3,748,325
     
3,099,311
 
Weighted average common shares outstanding, diluted
   
4,625,295
     
3,099,311
 





The following information was filed by Pds Biotechnology Corp (PDSB) on Tuesday, May 14, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Pds Biotechnology Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pds Biotechnology Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account